Real-World Evidence in Rare Diseases: Accelerating Market Access

LEARNING OBJECTIVES

Why are market access opportunities and challenges for OMPs different from other drugs?

Why are market access opportunities and challenges for OMPs different from other drugs?

How to collaborate with patients & caregivers in rare conditions to generate patient-meaningful outcomes?

How to collaborate with patients & caregivers in rare conditions to generate patient-meaningful outcomes?

Leveraging applications of RWE for pricing and access success and throughout the lifecycle

Leveraging applications of RWE for pricing and access success and throughout the lifecycle

To mitigate payer uncertainty by addressing the challenge of early market access with accelerated approvals and fewer clinical data

To mitigate payer uncertainty by addressing the challenge of early market access with accelerated approvals and fewer clinical data

How to develop a next-generation market access strategy with a life-cycle full spectrum evidence generation plan that maximizes product value from launch to loss of exclusivity?

How to develop a next-generation market access strategy with a life-cycle full spectrum evidence generation plan that maximizes product value from launch to loss of exclusivity?

To differentiate and succeed in the increasingly competitive rare disease space with a ‘fast to patient’ approach

To differentiate and succeed in the increasingly competitive rare disease space with a ‘fast to patient’ approach